European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy
MILAN, Italy, June 06, 2025 – Italfarmaco S.p.A. announced today that the…
ServiceTitan Announces Fiscal First Quarter Financial Results
LOS ANGELES, June 05, 2025 (GLOBE NEWSWIRE) -- ServiceTitan (NASDAQ: TTAN), the…
Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
46% reduction in the risk of disease progression or death, and 27%…
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor,…
New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than…